Your browser doesn't support javascript.
loading
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof, Emma C; de With, Mirjam; de Man, Femke M; Creemers, Geert-Jan; Deiman, Birgit A L M; Swen, Jesse J; Houterman, Saskia; Koolen, Stijn L W; Bins, Sander; Thijs, Anna M J; Laven, Marjan M J; Hövels, Anke M; Luelmo, Saskia A C; Houtsma, Danny; Shulman, Katerina; McLeod, Howard L; van Schaik, Ron H N; Guchelaar, Henk-Jan; Mathijssen, Ron H J; Gelderblom, Hans; Deenen, Maarten J.
Afiliação
  • Hulshof EC; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.
  • de With M; Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • de Man FM; Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Deiman BALM; Department of Molecular Biology, Catharina Hospital, Eindhoven, the Netherlands.
  • Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Houterman S; Department of Education and Research, Catharina Hospital, Eindhoven, the Netherlands.
  • Koolen SLW; Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Bins S; Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Thijs AMJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Laven MMJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Hövels AM; Hovels Consultancy HTA and Health Economics, Bilthoven, the Netherlands.
  • Luelmo SAC; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Houtsma D; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands.
  • Shulman K; Department of Medical Oncology, Carmel Medical Centre and Clalit Haifa District Regional Oncology Clinics, Haifa, Israel.
  • McLeod HL; University of South Florida Taneja College of Pharmacy, Tampa, FL, USA.
  • van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Mathijssen RHJ; Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Deenen MJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: maarten.deenen@catharinaziekenhuis.nl.
Eur J Cancer ; 162: 148-157, 2022 02.
Article em En | MEDLINE | ID: mdl-34998046
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Glucuronosiltransferase / Neutropenia Febril Tipo de estudo: Clinical_trials / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Glucuronosiltransferase / Neutropenia Febril Tipo de estudo: Clinical_trials / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article